Limited studies have associated metformin with a reduced risk of viral associated cancers, however these had a number of methodological shortcomings. This study investigated whether the use of metformin is associated with a reduced risk of viral associated cancers in patients with type 2 diabetes. A cohort of 137,754 patients newly-prescribed non-insulin antidiabetic drugs between January 1, 1988 and March 31, 2016 was identified from the UK Clinical Practice Research Datalink and followed until a first-ever diagnosis of a viral associated cancer, death from any cause, end of registration with the practice, or March 31, 2016. Time-varying use of metformin was compared with use of other antidiabetic drugs, with exposures lagged by one year for latency purposes. Time-dependent Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) of incident viral associated cancer with use of metformin overall, by cumulative duration of use and viral etiology. Overall, there were 424 viral associated cancers during 759,810 person-years of follow-up (crude rate of 5.6 per 10,000 person-years). Metformin was not associated with a decreased rate of viral associated cancer (HR: 0.93, 95% CI: 0.65-1.32). There was no evidence of a duration-response relationship in terms of cumulative duration of use (p trend 5 0.69), including with use of metformin for more than 10 years (HR 1.02, 95% CI: 0.52-1.99), or by viral etiology. In this large population-based cohort study, the use of metformin was not associated with a reduced risk of viral associated cancer.
mutated (ATM) protein kinase-mediated DNA damage response (DDR) pathway that induces host homeostatic mechanisms. 10 It also may disrupt the enhanced glycolysis of tumorinitiating cells (Warburg effect), activate mitochondrial biogenesis and oxidative stress, and ultimately lower the threshold for senescence of tumor-initiating cells. 10 Oncoviruses induce carcinogenesis via the same DDR pathway on which metformin acts, 11, 12 thus it is biologically plausible that metformin may exert antitumor effects on viral associated cancers.
To date, few observational studies have been conducted to determine whether the use of metformin may affect the incidence of viral associated cancers. These studies have suggested protective effects of metformin on oropharyngeal and nasopharyngeal cancer, 13 cervical cancer 14 and hepatocellular carcinoma incidence. [15] [16] [17] [18] [19] [20] However, these studies had a number of important methodological shortcomings, including immortal time bias, 13, 14, 16, 17, 20 time window bias 15, 18, 19 and failed to account for cancer latency. 13, 14 Given the biological plausibility, additional carefully designed observational studies, using robust pharmacoepidemiological methods are warranted to evaluate the association between the use of metformin and incidence of viral associated cancers in patients with type 2 diabetes. Thus, the objective of this study was to determine whether the use of metformin is associated with a decreased incidence of viral associated cancers in patients with type 2 diabetes.
Methods

Data source
This study was conducted using the United Kingdom (UK) Clinical Practice Research Datalink (CPRD). The CPRD is a computerized database of longitudinal patient records, comprising data on over 14 million patients from over 700 general practices, which have been shown to be representative of the UK population. 21 The CPRD records demographic information, anthropometric data, lifestyle information, medical diagnoses and procedures, and prescription data which have been shown to be valid and of high quality. 22, 23 Importantly, cancer diagnoses recorded in the CPRD have been shown to be concordant with those recorded in the UK National Cancer Data Repository, including for viral associated cancers such as cervical cancer. 24 The study protocol was approved by the Independent Scientific Advisory Committee of the CPRD (protocol number 16_197 R) and by the Research Ethics Board of the Jewish General Hospital, Montreal, Canada.
Study population
We identified all patients aged at least 40 years of age, newly-prescribed non-insulin antidiabetic drugs (including metformin, sulfonylureas, prandial glucose regulators, thiazolidinediones, acarbose, dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide (GLP-1) agonists, sodiumglucose co-transporter-2 (SGLT2) inhibitors) between January 1, 1988 and March 31, 2015. Patients were eligible for inclusion if they had at least 12 months of continuous medical history in the CPRD prior to cohort entry. In addition, patients ever prescribed insulin prior to their first noninsulin antidiabetic prescription were excluded as these likely represent those with advanced disease, as were those diagnosed with gestational diabetes or polycystic ovary syndrome as these are other indications for metformin. Furthermore, patients with a previous diagnosis of acute or chronic liver failure (including cirrhosis of the liver and alcoholic hepatitis) were excluded as metformin is contraindicated in these patients. Finally, those previously diagnosed with any cancer (other than non-melanoma skin cancer) prior to cohort entry were excluded.
All patients meeting the study inclusion criteria were followed until a first-ever diagnosis of viral associated cancers (defined below), death from any cause, end of registration with the practice, or end of the study period (March 31, 2016), whichever occurred first.
Outcome definition
The primary outcome of interest was a primary diagnosis of viral associated cancer defined as a composite outcome (including hepatocellular carcinoma, Kaposi sarcoma, T-cell leukaemia, Non-Hodgkin's lymphoma, B and T cell lymphoma, cervical cancer, anal cancer, penile cancer, vaginal cancer, vulvar cancer, oropharyngeal and nasopharyngeal cancer).
Exposure assessment
The use of metformin was included in the models as a timevarying variable, allowing patients to contribute both exposed and unexposed person-time to the analysis, after accounting for a one year lag period. Thus, patients were considered unexposed to metformin until one year after a first prescription and considered exposed thereafter for the remainder of follow-up. This lag period accounted for a biologically meaningful latency time window, given that short exposure duration is unlikely associated with cancer incidence and to minimize reverse What's new? Metformin, a common non-insulin antidiabetes drug, has been implicated in cancer protection, maybe through metabolic mechanisms by interfering with the Warburg effect. This large population-based study found no association of metformin use and protection from virally induced cancers including cervical, nasopharyngeal and liver cancer as well as Kaposi sarcoma and non-Hodgkin's lymphoma. The authors point out that previous studies have had a number of important methodological shortcomings, including immortal time bias, which defines the follow-up period during which the outcome under study could not occur, that may have led to exaggerated protective associations.
causality, that is, exposure might be initiated or terminated due to early signs or symptoms of cancer. Based on this definition, patients were classified into two mutually-exclusive categories at the time of the risk set (i.e., time of the event): metformin (alone or in combination with other antidiabetic drugs) and other antidiabetic drugs.
Primary analysis investigated the use of metformin (compared to other antidiabetic drugs) until the time of event. Based on the above exposure definition, we also defined the use of metformin in terms of cumulative duration of use. This was defined, in a time-dependent fashion, as the total number of years of use calculated by summing the durations associated with each prescription between cohort entry and the risk set date.
Potential confounders
All models were adjusted for the following potential confounders measured at cohort entry: age, sex, year of cohort entry, alcohol-related disorders (including alcoholism, alcoholic cirrhosis of the liver, alcoholic hepatitis and hepatic flexure), smoking status (current, former, never, unknown) and BMI (<25 kg/m , unknown). Furthermore, to control for diabetes severity, models were adjusted for glycated hemoglobin (HbA1c) level (most recent laboratory result before cohort entry) and diabetes duration before cohort entry (defined as the time between either the first HbA1c level (>7.0%) or date of type 2 diabetes diagnosis, and cohort entry). Finally, models were adjusted for a history of vaccinations any time prior to cohort entry (including HPV and HBV), a diagnosis of HBV or HCV infection and HIV status any time prior to cohort entry and the use of immunosuppressive drugs in the year prior to cohort entry (including those listed in the British National Formulary chapter 8.2; Drugs affecting the immune response).
Statistical analyses
We used descriptive statistics to summarize the characteristics of the cohort. Crude incidence rates of viral associated cancer and 95% confidence intervals (CIs) based on the Poisson distribution were calculated for metformin users and users of other antidiabetic drugs. For the primary analysis, a time-dependent Cox proportional hazards model was used to estimate hazard ratios (HRs) and 95% CIs of viral associated cancer associated with the use of metformin compared with the use other antidiabetic drugs. All models were adjusted for the potential confounders listed above.
Secondary analyses
We conducted two secondary analyses. First, analysis investigated whether there was a duration-response relationship between metformin cumulative duration of use and viral associated cancer incidence according to the following four predefined categories: 5 years, 5.1-10 years and > 10 years. Linear trend was assessed by considering these three categories as a continuous variable in the models. In addition, duration of use was modeled as a continuous variable using a restricted cubic spline model with five knots to produce a smooth curve of the HR as a function of these time variables. 25, 26 Second, the primary analysis was repeated estimating HRs and 95% CIs associated with metformin use when stratifying cancer sites by viral etiology; including HPV associated cancers (cervical, anal, penile, vaginal, vulvar and oropharyngeal cancers), EBV associated cancer (Burkett's lymphoma, Hodgkin's lymphoma, Diffuse B cell lymphoma and nasopharyngeal cancer), HCV and HBV associated cancer (hepatocellular carcinoma), HTLV-1 (T cell leukaemia or lymphoma) and HHV8 (Kaposi sarcoma). For analysis of HPV associated cancer, patients who had a history of hysterectomy were excluded as it was not possible to determine if these were total or subtotal (i.e., where the cervix can remain).
Sensitivity analyses
We conducted five sensitivity analyses to assess the robustness of our findings. First, given uncertainties related to the length of the latency time window, analyses were conducted varying the length of the exposure lag period to two and three years. Second, we repeated the primary analysis using an alternative comparator group, comparing metformin to sulfonylureas (alone or in combination with other antidiabetic drugs). Third, analysis investigated competing risks due to deaths from any cause, utilising the sub-distribution hazards model proposed by Fine and Gray. 27 Fourth, we repeated the primary analysis using multiple imputation for variables with missing values. 28, 29 An ordinal logistic regression model was used to impute variables with missing information (including HbA1c level, smoking and BMI) with explanatory variables and cumulative hazard (as recommended 30 and metformin use at cohort entry), along with all confounders mentioned previously. Ten imputations were conducted, and the results combined using Rubin's rules. 31 Finally, we conducted a marginal structural Cox proportional hazards model to address potential time-dependent residual confounding during the follow-up period (Supporting Information Method 1). 32, 33 All statistical analyses were conducted using SAS version 9.4 (SAS institute, Cary, NC).
Results
The cohort included 137,754 patients with diabetes ( Fig. 1) , followed for a mean (standard deviation [SD]) of 5.5 (4.2) years. Overall, there were 424 viral associated cancer events during a follow-up of 759,810 person-years, generating a crude incidence rate of 5.6 (95%CI: 5.1-6.1) per 10,000 person-years. A total of 125,237 (90.9%) patients were prescribed metformin during the follow-up period.
Baseline characteristics for the cohort and by metformin therapy use at baseline are presented in Table 1 . Compared with users of other antidiabetic drugs, metformin users were younger and were more likely to have had alcohol-related disorders. In addition, metformin users were more likely to have been past smokers, to have a higher BMIs, and to have a lower HbA1c value. Finally, metformin users were more likely to have a previous diagnosis of HBV or HCV and were less likely to have used immunosuppressive drugs in the year prior to cohort entry.
The results of primary and secondary analyses are presented in Table 2 . Compared with the use of other antidiabetic drugs, the use of metformin was not associated with an overall decreased risk of viral associated cancers (0.5 vs 0.6 per 1,000 person years, respectively; adjusted HR: 0.93, 95% CI: 0.65-1.32). Similarly, in secondary analysis investigating cumulative duration of metformin use, there was no evidence of a duration response, with HRs around the null value across all duration categories (P for trend 5 0.69). Likewise, in the restricted cubic spline model the risk of viral associated 
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cancers remained relatively constant around the null value until 10 years of use (Fig. 2) . While the risk was elevated after 10 years in the restricted cubic spline model, this is based on unstable estimates due to a low number of events (22 events between 10 and 22 years cumulative duration of use). Similarly, in secondary analyses of cancer sites by viral etiology, null associations were observed with metformin use across all groups (Supporting Information Table 1 ). 3 Adjusted for age, sex, year of cohort entry, body mass index, smoking, alcohol related disorders, hemoglobin A1c, diabetes duration, previous diagnosis of HBV or HCV infection, use of immunosuppressive drugs in the year prior to cohort entry. Previous HPV or HBV vaccination not included in the model due to no exposed events.
Sensitivity analyses
Sensitivity analyses are presented in Figure 3 and Supporting Information Tables 2-5 . Varying the length of the lag period to 2 and 3 years yielded similar estimates to the primary analyses (HR: 0.91; 95%CI 0.63-1.31 and HR:0.87; 95% CI: 0.59-1.29, respectively). Results also remained consistent when using an alternative comparator group of sulfonylureas (HR: 0.86; 95% CI: 0.61-1.21), and in analysis accounting for competing risks due to death from any cause (HR: 0.99; 95% CI: 0.70-1.41). Similarly, null associations were observed in analyses using multiple imputation for missing data (HR: 0.94; 95% CI 0.66-1.33) and in the marginal structural model (HR: 0.92; 95% CI: 0.64-1.31).
Discussion
In this large population based study, metformin use was not associated with a decreased risk of viral associated cancer overall or when stratifying by viral etiology. Similarly, there were no associations with accumulating durations of metformin use. These findings remained consistent across several sensitivity analyses. While our study found null associations between metformin and viral associated cancers, other studies have reported protective associations with some individual cancer sites. A recent study utilising the National Health Insurance in Taiwan observed associations with oropharyngeal and nasopharyngeal cancer risk (HR: 0.36; 95% CI 0.17-0.74; HR: 0.50; 95% CI 0.31-0.80, respectively). 13 Similarly, a recent study investigating the association between metformin use and cervical cancer risk also reported similar reductions in risk (HR: 0.56 95% CI 0.40-0.78).
14 Moreover, similar risk reductions were observed in studies investigating associations between metformin and the incidence of hepatocellular carcinoma, with estimates ranging from 0.06 to 0.67. [15] [16] [17] [18] [19] [20] In contrast, one recent study reported null associations similar to that observed in this study (HR:1.10 95% CI 0.66-1.84) 34 while another study reported increases in hepatocellular carcinoma risk with metformin use (HR:1.25 95% CI 1.06-1.47). 35 However, the latter study was not limited to patients with type 2 diabetes. Many of these studies also had important timerelated biases, most notably immortal time bias. 36 Specifically, the use of time-fixed exposure definitions leads to the misclassification of person-time prior to the first metformin prescription as exposed. As a result patients must survive from cohort entry to the first metformin prescription to be considered exposed. Therefore, those who have a cancer diagnosis prior to the first metformin prescription during follow-up are included in the unexposed group. This bias is the likely explanation for the exaggerated protective effects of metformin in these previous studies. Likewise, many of these studies also had other important limitations including time-window bias, 15, 18, 19 introduced via the use of time-windows of different lengths between cases and controls to define exposure, 37 and failing to account for latency considerations. Overall, the results from this study do not support the biological hypothesis that metformin may reduce the incidence of viral associated cancers. It is hypothesized metformin may induce antineoplastic properties by influencing the same ATM pathway as oncoviruses, stimulating AMPK activation thus limiting the activity of the PI3K/AKT/mTOR signaling pathway and down regulating cellular proliferation. 38 Indeed, preclinical studies have shown these effects in both cervical cancer 39 and HPV associated oral squamous carcinoma models, 40 as well as HBV infected cell lines in which metformin modulated HBV transcriptional factors. 41 Despite this, it is unclear whether these chemoprotective properties of metformin can be translated at the population level. Notably, metformin concentrations used in these experiments exceed those used in clinical practice for the treatment of type 2 diabetes and therefore the latter may be too low to exert meaningful effects on cancer incidence. In addition these models do not account for the complex mechanisms of diabetes or capture comorbidities, lifestyle factors and other drug exposures common in patients with type 2 diabetes.
Strengths and limitations
This was the first study to investigate the association of metformin and viral associated cancers collectively, as well as the first to investigate some viral associated cancer sites such as Non-Hodgkin's lymphoma. Importantly, this study used a time-dependent exposure definition, thus avoiding immortal time bias and exposures were lagged for latency purposes. In addition we utilized a new user design, minimizing biases related to the inclusion of prevalent users. 42 Finally, models were adjusted for several potential confounders, and a marginal structural model analysis was conducted to adjust for potential time dependent confounders, which yielded similar results.
This study also has some limitations. Prescriptions in the CPRD represent those written by general practitioners, and thus misclassification of exposure is possible. However, since all patients entering the cohort were those newly treated with antidiabetic drugs, misclassification is likely minimal and non-differential between exposure groups. Secondly residual confounding from unmeasured or unknown variables is possible. Misclassification of the outcome is also possible, although cancer has been shown to be well recorded in the CPRD when compared with the UK National Cancer Data Repository, including cancer sites included in our outcome definition such as cervical cancer. 24 Finally, while some of these cancers are relatively common within the UK, including for example head and neck cancers and non-Hodgkin's lymphoma, 43 some viruses and their associated cancers are rare within European populations. 44 Therefore further investigations in populations with higher rates of oncoviruses may be warranted.
Conclusions
In summary, this study found no evidence that the use of metformin is associated with a decreased risk of viral associated cancers in patients with type 2 diabetes. Results remained consistent across secondary and sensitivity analyses. While this study does not support previous biological and observational evidence that metformin may decrease the incidence of viral associated cancers, it remains unclear whether metformin may influence the progression of these cancers. Thus, additional studies are needed to investigate the effects of metformin in that setting.
